Leprosy drug clofazimine activates peroxisome proliferator-activated receptor-γ and synergizes with imatinib to inhibit chronic myeloid leukemia cells


Disclosures: 1. SS acknowledges mission-mode in-house project for cancer from CSIR, NC acknowledges funding from CSIR network project ASTHI and AKT acknowledges funding from CSIR network project INDEPTH. The authors acknowledge sophisticated analytical instrument facility at CSIR-CDRI for FACS studies. HK, SoS, SC & RK were supported by fellowship from University Grants Commission. AKS, SK, AG, SD, KL, RM were supported by fellowships from CSIR. ND was supported by a fellowship from DBT. 2. No commercial sponsors were involved for this study. NC was a consultant through CSIR-CDRI for projects unrelated to this work with GSK and Glenmark. SS did a sponsored research through CSIR-CDRI for Sphaera Pharma for a project unrelated to this work. 3. A patent application has been filed using part of the data from this work: Titled: Combination of Clofazimine and Imatinib for effective therapy of drug-resistant myeloid leukemia. File number: 140NF2017 4.DP, JM, KGD, NY, AC and MRJ are employees of Zydus Research Center, the research and development arm of Cadila Healthcare Ltd., Ahmedabad, India. Collaboration with Zydus Research Center was strictly academic.

Contributions: HK, SC, ND, SoS, DP, JM AG, SK, AKS, SD, KL, RK, RM, KGD, NY, ALV performed experiments. JRG, AC, MRJ, SB, AKT, NC, RR, SS designed and supervised experiments; AnKT provided patient samples and did the BCR-ABL1 mutation analysis. All authors contributed to data analysis. HK and SS wrote the manuscript, NC edited the manuscript.